Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma

Trial Profile

Phase II Evaluation of Concurrent Ipilimumab Therapy and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Malignant Melanoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Nov 2014 Planned End Date changed from 1 Sep 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov.
    • 29 Apr 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 21 Aug 2012 Actual initiation date (Aug 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top